MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$3,217K
EPS
-$0.07
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Income tax benefit
-
-
0*
-
License revenue
-
300
-
-
General and administrative
2,027
2,072
-3,021*
1,889
Research and development
1,268
355
1,848*
2,551
In-process research and development impairment
-
-
0*
-
Total operating costs and expenses
3,295
2,427
-1,173
4,440
Gain from operations
-3,295
-2,127
1,173*
-4,440
Foreign currency exchange (gain) loss
-1
1
-26*
14
Interest income
79
82
109*
65
Total other income
78
83
83*
79
Net gain before income taxes
-3,217
-2,044
1,255*
-4,361
Profit Loss
-
-
1,255*
-
Deemed Dividend From Warrant Inducement
-
-
375*
-
Net gain attributable to common stockholders
-3,217
-2,044
880
-4,361
Basic EPS
-0.07
-0.05
0.044
-0.45
Diluted EPS
-0.07
-0.05
0.044
-0.45
Basic Average Shares
45,892,668
41,072,725
19,992,617
9,676,521
Diluted Average Shares
45,892,668
41,072,725
19,992,617
9,676,521
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net gain
attributable to common...
-$3,217K
(75.36%↑ Y/Y)
Interest income
$79K
(46.30%↑ Y/Y)
Net gain before
income taxes
-$3,217K
(75.36%↑ Y/Y)
Total other income
$78K
(5.41%↑ Y/Y)
Foreign currency
exchange (gain) loss
-$1K
(-105.00%↓ Y/Y)
Gain from operations
-$3,295K
(74.91%↑ Y/Y)
Total operating costs
and expenses
$3,295K
(-74.91%↓ Y/Y)
General and
administrative
$2,027K
(-81.87%↓ Y/Y)
Research and development
$1,268K
(-35.07%↓ Y/Y)
Buy us a coffee
Theriva Biologics, Inc. (TOVX)
Theriva Biologics, Inc. (TOVX)